Randomised, double blind, multicentre, placebo controlled phase III study of the safety and tolerability following administration of live attenuated JE [Japanese encephalitis] vaccine (ChimeriVax-JE)
Phase of Trial: Phase III
Latest Information Update: 08 Jun 2016
At a glance
- Drugs Japanese encephalitis vaccine (Primary)
- Indications Japanese encephalitis
- Focus Adverse reactions; Registrational
- Sponsors Sanofi Pasteur Holding
- 08 Jul 2011 New source identified and integrated (Australian New Zealand Clinical Trials Registry, ACTRN12605000575639).
- 26 Jan 2009 Actual end date (Nov 2006) added as reported by ClinicalTrials.gov.
- 26 Jan 2009 Actual initiation date (Oct 2005) added as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History